Immune Targeting Systems (United Kingdom) a clinical-stage biopharma focused on synthetic vaccines for seasonal influenza strains, closed a $13.2M Series A financing, bringing the total round to $20.2M. Participants include Novartis Venture Funds, HealthCap, Truffle Capital and London Technology Fund.